PepGen Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
PEPG$4.61+92.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OFSTOCKHOLDERS’ EQUITY
(IN THOUSANDS, EXCEPT SHARE AMOUNTS)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive(Loss) · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity (Deficit) | |
| Balance as of December 31, 2023 | 23,823,241 | $2 | $289,867 | $34 | $(181,482) | $108,421 |
| Issuance of stock in public offering, net of underwriters' fees and issuance costs of $3,730 | 7,530,000 | 1 | 76,351 | — | — | 76,352 |
| Issuance of common stock from At-the-Market Sales Agreement, net of underwriters' fees of $100 | 1,000,000 | — | 9,900 | — | — | 9,900 |
| Exercise of stock options | 36,194 | — | 395 | — | — | 395 |
| Stock-based compensation expense | — | — | 2,022 | — | — | 2,022 |
| Unrealized loss on marketable securities | — | — | — | (20) | — | (20) |
| Cumulative translation adjustment arising during the period | — | — | — | (51) | — | (51) |
| Net loss | — | — | — | — | (18,020) | (18,020) |
| Balance as of March 31, 2024 | 32,389,435 | 3 | 378,535 | (37) | (199,502) | 178,999 |
| Exercise of stock options | 128,354 | — | 1,403 | — | — | 1,403 |
| Issuance of stock under the employee stock purchase plan | 32,614 | — | 149 | — | — | 149 |
| Stock-based compensation expense | — | — | 2,862 | — | — | 2,862 |
| Unrealized loss on marketable securities | — | — | — | (37) | — | (37) |
| Cumulative translation adjustment arising during the period | — | — | — | (1) | — | (1) |
| Net loss | — | — | — | — | (28,335) | (28,335) |
| Balance as of June 30, 2024 | 32,550,403 | 3 | 382,949 | (75) | (227,837) | 155,040 |
| Exercise of stock options | 39,299 | — | 407 | — | — | 407 |
| Stock-based compensation expense | — | — | 3,226 | — | — | 3,226 |
| Unrealized gain on marketable securities | — | — | — | 186 | — | 186 |
| Cumulative translation adjustment arising during the period | — | — | — | (20) | — | (20) |
| Net Loss | — | — | — | — | (21,384) | (21,384) |
| Balance as of September 30, 2024 | 32,589,702 | $3 | $386,582 | $91 | $(249,221) | $137,455 |
| Balance as of December 31, 2022 | 23,713,196 | $2 | $282,566 | $(81) | $(102,856) | $179,631 |
| Stock-based compensation expense | — | — | 1,348 | — | — | 1,348 |
| Exercise of stock options | 68,709 | — | 130 | — | — | 130 |
| Net loss | — | — | — | — | (16,319) | (16,319) |
| Cumulative translation adjustment arising during the period | — | — | — | 53 | — | 53 |
| Balance as of March 31, 2023 | 23,781,905 | 2 | 284,044 | (28) | (119,175) | 164,843 |
| Stock-based compensation expense | — | — | 1,837 | — | — | 1,837 |
| Exercise of stock options | 31,642 | — | 85 | — | — | 85 |
| Net loss | — | — | — | — | (19,522) | (19,522) |
| Cumulative translation adjustment arising during the period | — | — | — | 41 | — | 41 |
| Balance as of June 30, 2023 | 23,813,547 | 2 | 285,966 | 13 | (138,697) | 147,284 |
| Stock-based compensation expense | — | — | 1,941 | — | — | 1,941 |
| Cumulative translation adjustment arising during the period | — | — | — | (70) | — | (70) |
| Net loss | — | — | — | — | (23,290) | (23,290) |
| Balance as of September 30, 2023 | 23,813,547 | $2 | $287,907 | $(57) | $(161,987) | $125,865 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.